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Background: This pilot study explores a therapeutic setting combining transcranial direct 
current stimulation (tDCS) and mindfulness-based cognitive therapy (MBCT) for patients 
with drug-resistant depression. tDCS has shown efficacy for depression treatment and 
improvement could be maintained with the combination with mindfulness, which has 
shown depression relapse-prevention properties.
Methods: Thirty-one treatment-resistant depressed patients have been assigned to our 
experimental treatment condition [tDCS combined with MBCT (n = 15)] or to a control 
condition [tDCS combined with relaxation (n = 16)]. Patients have completed both an 
intensive treatment block (eight consecutive days) and a single remind session 2 weeks 
after the intensive treatment. Clinical (depression, anxiety, and rumination) and cognitive 
(general cognitive functioning, mental flexibility, and working memory) symptoms of 
depression have been assessed through different questionnaires at baseline (t0), after the 
first block of treatment (t1), and after the remind session (t2).
Results: Results seem to indicate a positive impact of both treatment conditions on clinical 
and cognitive symptoms of depression at t1. However, the treatment condition combining 
tDCS with mindfulness has been found to better maintain clinical improvements at t2 
regarding some clinical [Montgomery–Åsberg Depression Rating Scale (MADRS) and 
Sadness and Anger Ruminative Inventory (SARI)] and cognitive variables (Digit Span-F 
and Digit Span-B).
Conclusion: Based on the current observations, a multi-disciplinary treatment approach 
combining tDCS and MBCT might be effective in resistant depressed patients in the long 
run, even though further clinical research is necessary.
Keywords: major depressive disorder, transcranial direct current stimulation (tDCS), mindfulness-based cognitive 
therapy, rumination, cognitive control
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inTRODUCTiOn
Major depressive disorder (MDD) is a highly prevalent condition 
in which patients experience a daily sustained negative affect and 
a persistent reduction in positive affect. Diverse questions remain 
to be elucidated to find out why those depressed individuals 
cannot just swap out of negative vibes. However, until now, MDD 
is mostly considered as a disease of impaired emotion regulation 
characterized by excessive negative ruminations hijacking the 
patients’ mental life and impacting their mood. As a matter of 
fact, rumination is now regarded as a maladaptive emotion-
regulation strategy at the center of depression processes (1), 
which mainly increases the hallmark symptoms of depression 
(for a meta-analysis, see 2).
Ruminations: Cognitive Deficits and 
Modified Brain Activity
Various alterations in cognitive functioning indexed by modified 
brain activity are thought to subtend the use of this maladaptive 
emotion-regulation strategy instead of other adaptive ones. 
Indeed, some specific cognitive deficits have been identified as 
potentially leading people to engage in ruminative processes 
(3). For instance, it has been shown that deficits in attention 
and working memory make negative content more accessible 
to depressed individuals, as negative mood has been found to 
be more frequently related to negative attention bias towards 
emotional information (4, 5) and to greater accessibility of 
negative memories (6; for a review, see 7). Last but not least, 
deficits in cognitive control and, particularly, cognitive inhibition 
(one of its pivots) have been identified in patients with MDD and 
are thought as a potentially main causal factor in rumination 
(8–11; cited in 12). Importantly, rumination and linked cognitive 
deficits have been related to a particularly modified brain activity: 
a hyper-activated amygdala region, which is insufficiently 
controlled by an hypo-activated prefrontal region (13), leading 
to an unsatisfactory cognitive control of emotions (3–11, 12, 14).
Treatments: Medication, Psychotherapy, 
and neuromodulation Techniques
Those observations are probably relevant enough to impact 
depression treatments. As a matter of fact, if usual treatments 
for the disease directly target the limbic hyperactivity through 
pharmacotherapy (i.e., antidepressant medication), the common 
use of antidepressant medication, sometimes combined with 
psychotherapy, leaves numerous patients with unsatisfactory 
responses in terms of both remission and relapse and chronicity 
(15). Some researchers even consider that two of three MDD 
patients retain with depression symptoms after a first-line 
treatment (16, 17). Moreover, depression often shows a chronic 
course and various relapses (5, 18). Apart from their insufficient 
efficacy, antidepressant medications are often characterized by 
important secondary effects (19, 20) leading to a weak treatment 
adherence (21). Therefore, noninvasive brain stimulation 
techniques (NIBS), such as repetitive transcranial magnetic 
stimulation (rTMS) and transcranial direct current stimulation 
(tDCS), have been raising interest for their potential therapeutic 
efficacy in different psychiatric and neurological conditions. 
Indeed, in many neuropsychiatric diseases, such as depression, 
an important pathophysiological factor has been identified: the 
alteration of neuroplasticity and of cortical excitability. About 
50 years ago, some researchers had already observed that the 
application of transcranial direct current can induce a sufficiently 
important current flow to achieve physiological and functional 
effects in both healthy subjects and patients with psychiatric 
disorders (22). While this technique (tDCS) has been almost 
forgotten for the following years, more recent studies have 
redefined it as a tool to modulate human brain activity, and its 
physiological effects are starting to be systematically explored 
in various researches (22). In depressed patients, tDCS has 
especially been used in order to prime the neural system and 
to reinforce its hypo-activated prefrontal executive functioning 
(22). As a matter of fact, the hypo-activated prefrontal region 
(13), by insufficiently controlling the hyper-activated amygdala 
region, has been related to ruminations, which is considered as a 
main causal and maintenance factor of depression.
About tDCS in the Treatment 
of Depression
tDCS works by inducing neuronal plasticity via application of 
relatively weak currents through the scalp. It uses a constant low 
current (1–2 mA) delivered directly to the brain area of interest 
via electrodes positioned on the scalp, inducing intracerebral 
current flows (23). The device has an anodal electrode (the 
positively charged electrode, placed over the region of interest), 
which increases the excitability of the underlying cortex (24), and 
a cathodal electrode (the negatively charged electrode, placed in 
another location in order to create a circuit), which decreases the 
excitability of the underlying cortex (24).
Historically, Fregni and collaborators (25) were the first to 
describe the antidepressant effects of anodal tDCS over the right 
prefrontal dorsolateral cortex (rPFDLC). Since then, encouraging 
but controversial results have been found regarding the clinical 
outcomes of the application of tDCS in patients suffering from 
MDD. Indeed, different meta-analyses have been published. 
A recent one concluded to a probable efficacy of anodal tDCS 
of the left dorsolateral prefrontal cortex (DLPFC) (with right 
orbitofrontal cathode) in major depressive episode without 
drug resistance but no clinical effects of the anodal tDCS of the 
left DLPFC in drug-resistant major depressive episodes (22). 
Another recent meta-analysis concluded at a moderate efficacy of 
active tDCS in MDD compared with placebo stimulation (sham 
stimulation: inactive tDCS; in this kind of placebo stimulation, a 
very short duration current is applied that produces a sensation 
for the patients, but this current stops really quickly) (26). In fact, 
studies have explored the therapeutic effects of tDCS in different 
depressed patient samples (e.g., non-drug-resistant depression vs 
drug-resistant depression, and unipolar vs bipolar depression) 
in order to compare its efficacy to pharmacotherapy and/or as 
an add-on treatment to antidepressant medication (22). tDCS 
has showed antidepressant efficacy when used alone (27), but a 
significant synergic effect of active tDCS combined with classic 
antidepressant medication has been found in different studies 
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(28). For instance, in 2012, Brunoni et al. (29) have showed 
that a combined use of antidepressants and active tDCS offers 
better results than each modality alone. In 2013, the same 
research group has found a greater mood improvement after 
active tDCS combined with sertraline compared with all other 
groups. Importantly, the same study showed that active tDCS was 
significantly superior to placebo, but no differences were found 
between active tDCS and sertraline conditions (30). Besides, one 
of the most important studies to date was led on a sample of 245 
depressed patients who were assigned to different experimental 
conditions [high level of escitalopram (20 mg); high level of 
active tDCS – 1 stimulation per day for 15 days; 30 min; 2 mA; 
antidepressant placebo; sham stimulation with tDCS]. This 
study concluded to a higher efficacy of active tDCS compared 
with placebo condition but to a lower efficacy compared 
with escitalopram (20 mg). According to those results, active 
tDCS should then not be as effective as classic antidepressant 
medication (31). Importantly, some researchers have proposed 
that tDCS efficacy seems to diminish in patients with high 
therapeutic resistance (32). It remains to be clarified whether the 
probable therapeutic effects of tDCS are clinically meaningful 
and how to optimally perform tDCS in therapeutic settings for 
drug-resistant patients.
Significantly enough, to date, only few studies have 
explored a possible synergic effect between tDCSs and 
psychotherapeutic modalities in the treatment of depression. 
Moreover, researches exploring the combination between 
tDCS and various forms of cognitive therapies displayed 
contradictory results (26, 33).
About Mindfulness-Based Cognitive 
Therapy in the Treatment of Depression
This last decade, a specific version of cognitive therapy, 
mindfulness-based cognitive therapy (MBCT) (34), has been 
arousing interest in treating depression by preventing relapses 
(18, 35–41). MBCT, defined as the non-elaborative and non-
judgmental awareness that arises from deliberately paying 
attention to the present-moment experience with the attitude 
of curiosity and acceptance (42), has been associated with 
depression relapse-prevention properties by targeting the 
prefrontal executive functioning.
Indeed, the MBCT program developed by Segal et al. (34) 
consists of a group therapy of eight sessions (one session per 
week) in which the objective is for patients to learn to reckon 
and identify their cognitive and behavioral reactions following 
a low mood moment and/or in stressful situations and to 
consider them with an attitude of acceptance and kindness. This 
technique actually teaches MDD patients to disengage from 
negative automatic ruminations by training their attention and 
executive functioning abilities (34, 43–46). MBCT has also been 
shown to improve working memory abilities and to lead to a 
cerebral plasticity process by targeting the DLPFC and leading 
to higher activation of the DLPFC in some error-detection tasks 
after completing an MBCT program and an increase of the 
fronto-insular cerebral circuits when treating emotional negative 
stimuli. Those cerebral changes following MBCT program 
have been shown to be directly proportional to the amount of 
mindfulness practice (47).
It appears that tDCS has showed some efficacy as an 
antidepressant treatment (but the questions about its sustained 
effect through time remain unanswered) and that MBCT has 
been shown to be effective in preventing relapses, and we 
wanted to test their combined use. Furthermore, we suggest 
that we could optimize MBCT sessions in depressed patients 
if their hypo-activated neural system of PFDLC has first been 
primed with tDCS. That is, we think that tDCS application 
on patients’ PFDLC should optimize the ability to perform 
the MBCT program by allowing the patients to improve their 
attentional, cognitive inhibition and executive functioning 
abilities. To our knowledge, MBCT use in combination with 
tDCS has never been studied. Relaxation has been considered 
in our study as a placebo condition for MBCT. Indeed, somatic 
relaxation is a primarily body-awareness-based relaxation 
intervention (48). It consists in progressive muscle relaxation 
(using tensions and release of muscles throughout the body to 
relax), simple breathing techniques, and guided imagery to give 
a comprehensive course on stress reduction (i.e., focus on bodily 
relaxation). It has previously been used as a sham condition in 
studies on mindfulness effects (49, 50). If tDCS and MBCT act 
complementarily by both influencing the same neural circuits, we 
would expect an improvement of cognitive deficits in depressed 
patients, a diminution of ruminations, and lower depression 
scores after tDCS treatment to be better maintained through time 
in the MBCT condition compared with the relaxation condition. 
Indeed, we suggest that tDCS application on the left PFDLC of 
resistant depressed patients should optimize the ability to perform 
the MBCT program by allowing the patients to improve better 
than during the relaxation sessions, their attentional, cognitive 
inhibition and executive functioning abilities and by allowing 
them to disengage from automatic negative ruminations, which 
is maintaining their depression.
METhOD
Trial Design and Randomization
Treatment-resistant MDD patients were recruited by qualified 
psychiatrists on a clinical basis through the psychiatric services 
of CHU Brugmann (Brussels, Belgium) and Hospital Vincent 
Van Gogh (Marchienne-au-Pont, Belgium) from June 2015 to 
December 2016, as part of an initial pilot study. After a screening 
procedure led by the investigator (a clinical psychologist), 
selected patients were then successively integrated in different 
treatment groups following their inclusion order in the protocol. 
Each group was designed to include six patients. A total of eight 
treatment groups were necessary to include the initially recruited 
46 patients. Recruited patients have been randomly assigned to 
two experimental conditions: (1) the first group has received 
active tDCS on the left DLPFC (20 min; 2 mA) directly followed 
by 2-h MBCT group sessions; (2) the second group has received 
active tDCS on the left DLPFC (20 min; 2 mA) directly followed 
by a 30-min Jacobson relaxation session (Figure 2, randomization 
protocol). Due to the protocol structure and clinical implications, 
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it was impossible for the investigator to be blinded regarded the 
groups of enrolment (relaxation or mindfulness). Patients were 
informed during the first session that they were going to undergo 
relaxation or mindfulness. There were no important changes to 
methods after pilot trial commencement.
Participants
Forty-six treatment-resistant MDD patients have been recruited 
by qualified psychiatrists on a clinical basis through the 
psychiatric services of CHU Brugmann (Brussels, Belgium) and 
Hospital Vincent Van Gogh (Marchienne-au-Pont, Belgium). 
A screening procedure led by the investigator confirmed the 
inclusion criteria for all participants. That is, patients matched 
the following criteria: (1) diagnosis of non-psychotic unipolar 
MDD according to the Diagnostic and Statistical Manual of 
Mental Disorders, 5th Edition (DSM-V), confirmed by the 
Mini-International Neuropsychiatric Interview (MINI) and 
with a minimal depression baseline score of 15, which has been 
defined as the minimal score for the threshold of depression, at 
the Montgomery–Åsberg Depression Rating Scale (MADRS); 
(2) comorbidities with anxiety disorders and personality 
disorders, according to the DSM-V were allowed, but patients 
with other comorbidities, such as psychosis and addiction 
diseases, were excluded; (3) patients with any actual or 
antecedent of severe somatic and/or neurological diseases were 
excluded; (4) resistant depression has been defined as a failure 
to respond to at least two antidepressant medications; and (5) 
patients included in our study have been allowed to continue 
their personal antidepressant medication, which has been 
controlled to be stable for at least 6 weeks before beginning and 
during the treatment. Benzodiazepines have been accepted up 
to a maximal dose of 20 mg diazepam equivalent per day. (6) 
Patients have been allowed to pursue their eventual individual 
psychotherapy, except for cognitive-behavioral therapy (CBT); 
and (7) patients with a previous background of mindfulness 
and/or neurostimulation techniques have been excluded. 
Note that the local ethics committees of CHU Brugmann and 
Hospital Vincent Van Gogh approved the study. Informed 
written consent to participate in the study was obtained from 
all participants after they received all aspects regarding the 
procedure details and the aims of the study. As mentioned 
before, among those 46 patients, 15 dropped out of our 
research protocol mostly due to their work schedules and to the 
highly energy-demanding protocol, so 31 patients were finally 
included in the present experiment.
Procedures
Our main aim was to assess the impact of “combining MBCT 
with active tDCS.” The efficacy of this combined treatment (active 
tDCS on the DLPFC + MBCT) on the cognitive and clinical 
symptoms of depression was then investigated by comparing 
it with a procedure in which active tDCS was coupled with a 
“non-MBCT technique,” that is, relaxation (which was classically 
used as a sham condition in studies on mindfulness effects; 49, 
50). Therefore, 31 patients have been randomly assigned to two 
experimental conditions: (1) the first group has received active 
tDCS on the left DLPFC (20 min; 2 mA) directly followed by 2-h 
MBCT group sessions (MBCT condition 1; n = 15), and (2) the 
second group has received active tDCS on the left DLPFC (20 
min; 2 mA) directly followed by a 30-min Jacobson relaxation 
session (relaxation condition; n = 16).
interventions
Patients from the two experimental conditions have been 
invited to take two blocks of treatment. That is, in block 1, 
patients have been invited to eight consecutive days where 
they have received daily an individual active tDCS on the left 
PFDLC (20 min; 2 mA) directly followed by a 2-h MBCT group 
session (daily session inspired by the program developed 
by 34) or a 30-min relaxation session (51; and in block 2, 
patients received a remind session 2 weeks after the first 
block of treatment.
For the tDCS, participants were seated in a circle in a group 
including between three and six people in a resting room with 
small lighting. Each participant received daily a 2-mA tDCS for 
20 min (i.e., 1,200 s), with a fade-in period of 15 s and a fade-out 
period of 15 s, during eight consecutive open days. The anode 
was systematically placed over the left PFDLC and the cathode 
over the right PFDLC anatomically located by the use of a Quik-
Cap referring to the electroencephalography international 
system 10–20 (anode located on F3 and cathode located on 
F4) (52). Both electrodes have been inserted in sponges soaked 
with saline solution to improve the conductivity and increase 
the patients’ comfort by limiting the risk of cutaneous lesion, 
before being placed over their respective brain areas. After 
having received tDCS, participants were invited either to a 
2-h MBCT session or to a 30-min Jacobson relaxation session 
depending on the experimental condition they were assigned 
to. For each experimental condition (MBCT or relaxation), 
sessions were moderated by the same clinical psychologist 
and took place in the same resting room with small lighting 
and controlled temperature. Also, the same material was used 
for each experimental condition: a yoga mat and a cushion 
per participant. Note that if, according to the MBCT program 
developed by Segal et al. (34), the eight classical MBCT sessions 
are normally offered at the weekly pace, in our research protocol, 
those eight sessions have been offered at a daily rhythm right 
after the active tDCS, in order to comply with the usual tDCS 
protocols used in depression.
Assessment and Outcomes
First, candidates for our study have been meeting for a 1-h 
appointment (screening) with a clinical psychologist in order to 
confirm the diagnosis of unipolar MDD according to DSM-V 
both through a psychological evaluation and through the 
MINI. Candidates matching the inclusion criteria were then 
selected for our research protocol. The day before the treatment 
beginning (t0), after receiving all study details and signing the 
informed consent form, every participant has been individually 
asked to complete both clinical and cognitive scales. First, they 
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have been asked to complete the clinical questionnaires that 
aimed to assess their clinical state. Then, they have been asked 
to complete cognitive questionnaires in the presence of the same 
clinical psychologist.
Clinical outcomes (depression, anxiety, and rumination) have 
been assessed through different clinical scales the day before the 
first block treatment (T0), the day right after the end of the first 
block treatment (T1), and the day right after the first remind 
session (T2) (Figure 1): MADRS (53), State-Trait Anxiety 
Inventory (STAI; 54), and the Sadness and Anger Ruminative 
Inventory (SARI; 55). Cognitive outcomes (general cognitive 
functioning, attention, working memory, and mental flexibility) 
have been assessed through different cognitive tests: Montreal 
Cognitive Assessment (MOCA; 56), Digit Span [Wechsler 
Adult Intelligence Scale (WAIS-IV); (57) and Trail Making Test 
(TMT; 58).
The primary efficacy outcome shall be assessed by the 
MADRS. The secondary outcomes will be assessed by the STAI 
and the SARI, and cognitive scores by MOCA, the Digit Span 
(WAIS-IV), and the TMT.
For the primary and secondary efficacy outcomes, obtained 
data in each experimental condition (group 1 and group 2) were 
analyzed with mixed, repeated-measures of variance model with 
scale scores as dependent within-subjects variables and treatment 
condition as between-subjects variable. Simple effects were 
inspected together with systematic examinations of interaction 
sources. Independent samples Student’s t-tests, chi-square tests, 
and Bonferroni’s post-hoc t-tests were used when relevant. All 
data analyses were performed with SPSS 20.00 at the level of 
significance set at 0.05.
Analyses
Obtained data in each experimental condition (group 1 
and group  2) were analyzed with mixed, repeated measures 
of variance model with scale scores as dependent within-
subjects variables and treatment condition as a between-
subjects variable. Simple effects were inspected together with 
systematic examinations of interaction sources. Independent 
samples Student’s t-tests, chi-square tests, and Bonferroni’s 
post-hoc t-tests were used when relevant. All data analyses 
were performed with SPSS 20.00 at the level of significance 
set at 0.05.
RESUlTS
Baseline Demographic, Clinical, and 
Cognitive Variables
Baseline demographic, clinical, and cognitive variables of the 
two groups (MBCT condition and relaxation condition) were 
analyzed by means of independent samples Student’s t-tests and 
chi-square tests when relevant. At baseline, MDD patients of 
the MBCT condition and the relaxation condition were similar 
in terms of demographic variables (age, gender, and educational 
level), of clinical variables (MADRS: hetero-evaluation of 
depression; STAI-E: auto-evaluation of state anxiety; SARI: auto-
evaluation of sadness ruminative behavior), and of cognitive 
variables (MOCA: general cognitive functioning; TMT: mental 
flexibility; Digit Span: working memory), confirming the 
correct matching between groups. All patients’ demographic, 
clinical, and cognitive baseline scores and p-value, obtained 
through independent samples Student’s t-tests, and chi-square 
tests when relevant, are summarized in Table 1.
impact of the Two Treatment Conditions 
[MBCT Condition (n = 15) and Relaxation 
Condition (n = 16)] on Clinical and 
Cognitive Symptoms of Depression After 
T1 and T2
With the idea of assessing an eventual immediate (t1) and longer-
term (t2) treatment conditions’ effect on clinical and cognitive 
symptoms of refractory depressed patients, we analyzed their 
clinical and cognitive scores with mixed, repeated measures of 
variance model with one dependent within-subjects variable 
[time (three levels: t0, t1, and t2)] and a between-subjects 
variable [treatment conditions (two groups)]. Obtained results 
are presented below both for the clinical assessment battery and 
for the cognitive assessment battery. Statistical corrections were 
applied when necessary. Means and SD scores of each clinical 
and cognitive scales at T0, T1 and T2 are presented for each 
treatment conditions in Table 2.
Clinical Battery
A time effect was found between t0, t1, and t2 regarding all 
clinical scores in both treatment conditions, that is, STAI-E 
scores [F(2, 58) = 12.755; p < 0.001***; η2 = 0.305; p = 0.996], 
MADRS [F(1,496, 43,391) = 49.72; p = 0.001***; η2 = 0.632; p = 
FigURE 1 | Treatment (white boxes) and assessment timeline (grey boxes). Treatment (white boxes) and assessment (grey boxes) timeline for both treatment conditions.
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1.000], and SARI [F(1,976, 57,310) = 12.679; p = 0.001***; η2 = 
0.304; p = 0.995].
No interaction effect between our within-subjects and 
between-subjects variables (time * treatment conditions) was 
observed for the STAI-E [F(2, 58) = 0.408; p = 0.640 > 0.05; 
η2 = 0.014; p = 0.113], while an interaction effect between our 
within-subjects and between-subjects variables (time * treatment 
conditions) has been found regarding the MADRS [F(1,496, 
43,391) = 7.252; p = 0.002**; η2 = 0.200; p = 0.924] and the SARI 
[F(1,976, 57,310) = 3.709; p = 0.03*; η2 = 0.304; p = 0.995].
Interestingly, when looking at automatically generated 
pairwise comparisons for the clinical evolution at the STAI-E, 
we observe that this score is significantly different between t0 
and t1 (p = 0.001***), not significantly different between t1 
and t2 (p = 1.000 > 0.05), and significantly different between 
t0 and t2 (p = 0.005**), indicating a significant improvement of 
state anxiety at t1 and a stabilization of this score at t2 for both 
treatment conditions.
With the idea of exploring the observed interaction effect (time 
* treatment conditions) for the MADRS and SARI, we conducted 
specific post-hoc analyses. After splitting our general sample into 
two independent samples, we conducted an independent t-test.
Regarding the MADRS, no significant differences were found 
at t0 [t(29) = −0.641; p = 0.526 > 0.05] and t1 [t(29) = −1.149; 
p = 0.260] between the two treatment conditions, but a significant 
difference was found at t2 [t(29) = −2.854; p = 0.008**]. Newly 
generated pairwise comparisons showed significant differences 
across three times for the MBCT condition [between t0 and t1 
(p = 0.001***), between t1 and t2 (p = 0.001***), and between t0 and 
t2 (p = 0.004**)], but for the relaxation condition, only between 
TABlE 1 | Comparison of demographic, clinical, and cognitive baseline scores (t0) between participants of the two treatment conditions.




Age MBCT condition 15 50 (5.38) 29 −0.16 0.901 > 0.05
Relaxation condition 16 50,31 (8.08)
Gender MBCT condition 15 N = 5/10 (M/F) 1 0.059 0.809 > 0.05
Relaxation condition 16 N = 6/10 (M/F)
Educational level MBCT condition 15 13.73 (2.73) 29 0.652 0.520 > 0.05
Relaxation condition 16 13.06 (2.97)
Clinical and antidepressant treatment characteristics
SSRI MBCT condition 15 N = 9 / / /
Relaxation condition 16 N = 8
SNRI MBCT condition 15 N = 5 / / /
Relaxation condition 16 N = 5
SNRI + SSRI MBCT condition 15 N = 1 / / /
Relaxation condition 16 N = 2
Comorbidities OCD MBCT condition 15 N = 2 / / /
Relaxation condition 16 N = 1
Comorbidities with social phobia MBCT condition 15 N = 0 / / /
Relaxation condition 16 N = 1
Clinical scores
MADRS MBCT condition 15 23.13 (6.8) 29 −0.641 0.526 > 0.05
Relaxation condition 16 24.75 (7.20)
STAI-E MBCT condition 15 57.20 (9.15) 29 −0.983 0.334 > 0.05
Relaxation condition 16 54.56 (6.61)
STAI-T MBCT condition 15 46.40 (9.88) 29 0.924 0.363 > 0.05
Relaxation condition 16 51.06 (15.67)
SARI MBCT condition 15 40.53 (7.03) 29 −1.576 0.126 > 0.05
Relaxation condition 16 45 (8.6)
Cognitive scores
MOCA MBCT condition 15 26.87 (1.72) 29 1.599 0.121 > 0.05
Relaxation condition 16 25.38 (3.2)
TMT (B-A) MBCT condition 15 45.67 (31.29) 29 −1.004 0.324 > 0.05
Relaxation condition 16 59.88 (45.64)
DS-F MBCT condition 15 8.07 (1.9) 29 1.023 0.315 > 0.05
Relaxation condition 16 7.44 (1.5)
DS-B MBCT condition 15 5.60 (1.95) 29 0.551 0.586 > 0.05
Relaxation condition 16 5.25 (1.57)
MBCT, mindfulness-based cognitive therapy; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin and norepinephrine reuptake inhibitor; OCD, obsessive 
compulsive disorder; MADRS, montgomery–åsberg depression rating scale; STAI, state-trait anxiety inventory; SARI, sadness and anger ruminative inventory; 
MOCA, montreal cognitive assessment; TMT, trail making test; DS-F, Digit Span Forward and DS-B, Digit Span Backward.
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t0 and t1 (p = 0.001***) and between t0 and t2 (p = 0.009**). 
Indeed, no significant difference was found between t1 and t2 
(p = 0.321 > 0.05) for the relaxation condition. Those results seem 
to indicate a significant improvement of depression across three 
times for the MBCT condition [t0 (M = 23.13; SD = 1.75); t1 
(M = 13.73; SD = 2.47); t2 (M = 9.8; SD = 2.56)], but not for the 
relaxation condition, whose subjects seem to show a significant 
improvement between t0 (M = 24.75; SD = 1.8) and t1 (M = 
17.25; SD = 1.84), but not between t1 and t2 (M = 19.06; SD = 
2.02) (Figure 2).
Regarding the SARI, no significant differences were found 
at t0 [t(29) = −1.576; p = 0.126 > 0.05] and t1 [t(29) = −1.597; 
p = 0.121 > 0.05] between the two treatment conditions, but a 
significant difference was found at t2 [t(29) = −2.692; p = 0.012*]. 
Newly generated pairwise comparisons showed significant 
differences between t0 and t1 (p = 0.018**) and between t0 and 
t2 (p = 0.007**) and not between t1 and t2 (p = 1.000) for the 
MBCT condition, but only between t0 and t1 (p = 0.002**), and 
not between t1 and t2 (p = 0.097 > 0.05) nor between t0 and t2 
(p = 0.924 > 0.05), for the relaxation condition. Those results 
seem to indicate a significant improvement of auto-evaluation 
of sadness ruminative behavior (SARI) at t1, and a stabilization 
of this score at t2 for the MBCT condition [t0 (M = 40.53; SD = 
7.03); t1 (M = 34.67; SD = 10.16); t2 (M = 33.53; SD = 10.82)], 
but not for the relaxation condition, whose subjects seem to 
show a significant improvement between t0 (M = 45; SD = 8.6) 
and t1 (M = 40.5; SD = 10.16), but not between t1 and t2 (M = 
43,69; SD = 10.17).
Cognitive Battery
A time effect was found between t0, t1, and t2 regarding all 
cognitive scores, that is, MOCA score [F(1,907, 55,296) = 24.575; 
p = 0.001***; η2 = 0.459; p = 1.000], the TMT score [F(2, 58) = 
6.632; p = 0.003**; η2 = 0.186; p = 0.898], the Digit Span-F score 
[F(2, 58) = 12.326; p = 0.001***; η2 = 0.298; p = 0.994], and the 
Digit Span-B score [F(1,98, 57,426) = 7.513; p = 0.001***; η2 = 
0.206; p = 0.931].
Importantly, no interaction effect between our within-subjects 
and between-subjects variables (time * treatment conditions) 
was observed for the MOCA score [F(1,907, 55,296) = 1.944; p = 
0.155 > 0.05; p = 0.387], neither for the TMT score [F(2, 58) = 
0.463; p = 0.632 > 0.05; p = 0.122], while an interaction effect 
between our within-subjects and between-subjects variables 
(time * treatment conditions) has been found regarding the Digit 
Span-F score [F(2, 58) = 9.259; p = 0.001***; η2 = 0.242; p = 0.971] 
and Digit Span-B score [F(1,98, 57,426) = 5.903; p = 0.005**; 
η2 = 0.169; p = 0.857].
FigURE 2 | Evolution of depression scores across time. MADRS, 
Montgomery–Åsberg Depression Rating Scale; tDCS, transcranial direct 
current stimulation; MBCT, mindfulness-based cognitive therapy.
TABlE 2 | Patient’s clinical and cognitive baseline scores (t0) and scores’ evolution at t1 and t2 for the two experimental conditions (MBCT condition and relaxation condition).
T0 T1 T2
Clinical variables N M (SD) N M (SD) N M (SD)
MADRS MBCT condition 15 23.13 (6.8) 15 13.73 (9.57) 15 9.80 (9.93)
Relaxation condition 16 24.75 (7.20) 16 17.25 (7.38) 16 19.06 (8.10)
STAI-T MBCT condition 15 57.20 (9.15) 15 56.07 (11.12) 15 49.67 (11.08)
Relaxation condition 16 54.56 (6.61) 16 52.63 (6.84) 16 53.31 (7.14)
STAI-E MBCT condition 15 46.40 (9.88) 15 37.80 (10.95) 15 37.80 (9.37)
Relaxation condition 16 51.06 (15.67) 16 43.81 (14.36) 16 45.56 (13.24)
SARI MBCT condition 15 40.53 (7.03) 15 34.67 (10.16) 15 33.53 (10.82)
Relaxation condition 16 45 (8.6) 16 40.50 (10.16) 16 43.69 (10.17)
Cognitive variables N M (SD) N M (SD) N M (SD)
MOCA MBCT condition 15 26.87 (1.72) 15 28.87 (1.76) 15 29.60 (0.82)
Relaxation condition 16 25.38 (3.2) 16 26.13 (2.87) 16 26.94 (2.46)
TMT (B-A) MBCT condition 15 45.67 (31.29) 15 34.67 (28.47) 15 34.93 (21.76)
Relaxation condition 16 59.88 (45.64) 16 42.25 (42.15) 16 40.63 (37.26)
DS-F MBCT condition 15 8.07 (1.9) 15 9.4 (2.19) 15 10.33 (2.16)
Relaxation condition 16 7.44 (1.5) 16 7.88 (1.74) 16 7.56 (2.06)
DS-B MBCT condition 15 5.60 (1.95) 15 6.4 (2.23) 15 7.53 (2.13)
Relaxation condition 16 5.25 (1.57) 16 5.38 (1.7) 16 5.38 (1.54)
MBCT, mindfulness-based cognitive therapy; MADRS, montgomery–åsberg depression rating scale; STAI, state-trait anxiety inventory; SARI, sadness and anger 
ruminative inventory; MOCA, montreal cognitive assessment; TMT, trail making test; DS, digit span.
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Interestingly, when looking at automatically generated 
pairwise comparisons for the cognitive evolution at the MOCA, 
we observe that this score is significantly different between 
t0 and t1 (p = 0.001***), significantly different between t1 
and t2 (p = 0.005**), and significantly different between t0 
and t2 (p = 0.001***), indicating a significant improvement 
of general cognitive functioning (MOCA) at t1 and at t2 for 
both treatment conditions. When looking at automatically 
generated pairwise comparison for the cognitive evolution at 
the TMT, we observe that this score is significantly different 
between t0 and t1 (p = 0.05*); significantly different between t0 
and t2 (p = 0.018**), and not significantly different between t1 
and t2 (p = 1.000 > 0.05), indicating a significant improvement 
of mental flexibility (TMT) at t1 and a stabilization of those 
scores at t2 in both treatment conditions.
With the idea of exploring the observed interaction effect 
(time * treatment conditions) for the Digit Span-F and Digit 
Span-B scores, we conducted specific post-hoc analyses. After 
splitting our general sample into two independent samples, we 
conducted an independent t-test.
Regarding the Digit Span-F, no significant differences were 
found at t0 [t(29) = 1.023; p = 0.315 > 0.05] between the two 
treatment conditions, but a significant difference was found 
at t1 [t(29) = 2.146; p = 0.040*] and t2 [t(29) = 3.652; p = 
0.001***] between the two treatment conditions. When looking 
at newly generated pairwise comparisons, we found significant 
differences across three times for the MBCT condition [between 
t0 and t1 (p = 0.042*), between t1 and t2 (p = 0.006**), and 
between t0 and t2 (p = 0.001***)] but no significant difference 
for the relaxation condition [between t0 and t1 (p = 0.505 > 
0.05); between t0 and t2 (p = 1.000 > 0.05); between t1 and t2 
(p = 0.408 > 0.05)]. Those results seem to indicate a significant 
improvement of the amount of retained numbers across three 
times for the MBCT condition [t0 (M = 8,06; SD = 0.49); t1 
(M = 9,4; SD = 0.567); t2 (M = 10.33; SD = 0.558)], but not 
for the relaxation condition, whose subjects seem to show no 
significant improvement between t0 (M = 7,43; SD = 0.37), t1 
(M = 7,87; SD = 0.437), and t2 (M = 7,56; SD = 0.516).
Regarding the Digit Span-B, no significant differences were 
found at t0 [t(29) = 0.551; p = 0.586 > 0.05] nor at t1 [t(29) = 
1.443; p = 0.160] between the two treatment conditions, but 
a significant difference was found at t2 [t(29) = 3.242; p = 
0.003**]. Further pairwise comparisons revealed a significant 
difference between t0 and t2 (p = 0.005**), but no significant 
difference between other times [between t1 and t2 (p = 0.097 > 
0.05)], nor between t0 and t1 (p = 0.269) for the MBCT condition. 
For the relaxation condition, no significant difference has been 
found [between t0 and t1 (p = 1.000 > 0.05); between t0 and t2 
(p = 1.000 > 0.05); between t1 and t2 (p = 1.000 > 0.05)]. Those 
results seem to indicate a significant improvement of working 
memory between t0 and t2 for the MBCT condition [t0 (M = 5.6; 
SD = 1.95); t1 (M = 6.40; SD = 2.23); t2 (M = 7.53; SD = 2.13)], 
but not for the relaxation condition, whose subjects seem to show 
no significant improvement between t0 (M = 5,25; SD = 1.57), t1 
(M = 5,38; SD = 1.7), and t2 (M = 5,38; SD = 1.54).




Our previously described results seem to indicate a positive 
impact of both combined treatment conditions on the clinical 
and cognitive symptoms of depression assessed by MADRS, 
SARI, STAI, MOCA, Digit Span-F, Digit Span-B, and TMT at 
t1. However, a treatment condition effect has been found at t2 
regarding depression (MADRS), sadness ruminative behavior 
(SARI), the number of retained numbers (Digit Span-F), 
and working memory (Digit Span-B). Those results seem to 
indicate a sustained efficacy at t2 of the tDCS–MBCT condition 
compared with the tDCS relaxation. We stipulated that tDCS and 
MBCT might act complementarily with MBCT, allowing to avoid 
relapse after the end of tDCS sessions. We, therefore, expected 
an improvement of cognitive deficits in depressed patients, a 
diminution of ruminations, and lower depression scores after 
tDCS treatment to be better maintained through time in the 
MBCT condition compared with the relaxation condition.
As a matter of fact, patients included in the relaxation 
condition (active tDCS on the left PFDLC + relaxation) display 
an improvement of depression (MADRS), sadness ruminative 
behavior (SARI), anxiety (STAI), working memory (Digit 
Span B), general cognitive functioning (MOCA), and mental 
flexibility (TMT) at t1. However, most of those scores stay stable 
at t2 (MADRS, STAI, SARI, MOCA, TMT, and Digit Span-F), 
indicating no significant improvement between t1 and t2 for 
the participants of the relaxation condition. As relaxation is 
being considered as a control condition for MBCT and other 
psychotherapeutic modalities such as CBT and/or interpersonal 
therapy (IPT) (49, 50) in depression, it might be stipulated 
that the positive effect observed in patients who received the 
relaxation condition is due to the tDCS’s impact. Indeed, in 2008, 
a review of 15 trials exploring the possibility of using relaxation 
as a first-line treatment for depression confirmed that relaxation 
was slightly better than no treatment or minimal treatment but 
not as effective as psychological therapies like CBT (59).
As the only subjects who seem to show a further significant 
improvement of depression (MADRS), auto-assessment of 
sadness ruminative behavior (SARI), the number of retained 
numbers (Digit Span-F), and working memory (Digit Span-B) 
between t1 and t2 are patients who received the MBCT condition, 
it might be suggested that combining tDCS and MBCT may be 
of clinical relevance for a longer-term maintenance of clinical 
improvements. This better efficacy of the MBCT condition for 
the maintenance of clinical improvements might be linked to 
the combined use of tDCS and MBCT. Both of those therapeutic 
techniques are influencing the same neural circuits and 
boosting related cognitive deficits such as attention, working 
memory, and executive functioning, thereby allowing patients 
to disengage from ruminations and allowing them to improve 
their clinical state.
We tested a new therapeutic setting combining tDCS with 
MBCT in patients with drug-resistant depression. Obtained 
results seem to support our hypothesis stipulating that tDCS and 
MBCT might have complementary action mechanisms allowing 
patients to disengage from ruminations, which is considered as 
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a main causal and maintenance factor of depression. However, 
some methodological considerations might have impacted our 
results. We present those limitations below with the idea of 
proposing new research parameters. Clinical implications are 
further discussed.
limitations and Perspectives
If obtained results are encouraging for the treatment of patients 
with resistant depression and that this study was of clinical 
relevance, we should to point out the difficulties we had to 
recruit and to carefully select therapy-resistant depressed 
patients. For instance, some depressed patients dropped 
out of our protocol, invoking some reasons such as their 
work schedules and mainly to the highly energy-demanding 
protocol. Indeed, one of the classical symptoms of depression 
is the lack of energy and motivation to get things done. Our 
research protocol was inevitably a highly demanding program 
in terms of time and energy for patients, as well as for the 
therapeutic team in charge of both tDCS and MBCT. That is, 
the sample sizes presented in our pilot study are smaller than 
the estimated number of patients we would need for further 
randomized controlled trial (RCT) study and this small sample 
size limits analyses of other variables such as the impact the 
type of antidepressant treatment [selective serotonin reuptake 
inhibitor (SSRI), serotonin and norepinephrine reuptake 
inhibitor (SNRI), and SSRI + SNRI] and of comorbidities 
with other psychiatric conditions such as anxious disorder 
[obsessive compulsive disorder (OCD) and social phobia]. But 
other considerations should also been highlighted.
First, about the tDCS use, this study explores the efficacy 
of a new combined-treatment model that includes a recent 
neuromodulation technique, as encouraging results have been 
found regarding the clinical outcomes of tDCS’s applications in 
patients suffering from depression. However, it also appears that 
no clear guidelines yet exist considering this tDCS technique, as 
the uncertainty principally remains regarding some technical 
and neuroanatomical considerations, such as the electrodes 
montages (two main montages exist for the application of 
tDCS in depression: active anodal tDCS of the left DLPFC, and 
the cathode is placed either over the right DLPFC or over the 
right orbitofrontal cortex), the current intensity, and the session 
repetition timing. That is, according to the very recent literature 
review of Lefaucheur et al. (22), numerous factors are thought to 
modulate the impact of tDCS on cortical excitability [distance 
and orientation of the axonal somatodendritic axis with respect 
to the electric field; baseline activity of neural networks and 
afferent synaptic inputs to direct current; spatial relationships 
between the stimulated active target field, its projections areas, 
and the resting surrounding structures; pathological alterations 
of transmitter systems; medication taken by patients (30); 
individual polymorphisms and the current intensity (60); session 
repetition timing (61, 62); and electrode sizes, areas, shapes, or 
montage]. Therefore, clinical effects provided by tDCS may vary 
across patients and studies according to many technical and 
neuroanatomical considerations and relationships (22). When 
designing protocols and interpreting the impacts of tDCS in 
patients with depression and other neuropsychiatric diseases, 
all these factors should definitely be taken into account. In 
our study, electrode sizes (35 cm2), shapes (rectangular), and 
montage have consistently been controlled. But some other 
factors might have influenced our patients’ stimulations such 
as the baseline activity of neural networks and individual 
polymorphisms.
Also, in our study, we used a current intensity of 2 mA. 
Nevertheless, a recent interesting communication of Vöröslakos 
et al. (63) establish that neuronal circuits are affected by intensity 
currents that are higher than those used in conventional 
protocols such as 2 mA. Further research definitely should 
continue to explore the adequate tDCS parameters in terms of 
current intensity, electrodes montages, and stimulation duration.
Importantly, some recent studies (64) have found that 
significant reduction in depressive symptoms with tDCS appears 
after 6 weeks of treatment, while our protocol was designed for 
a first block of treatment of eight consecutive days and a second 
block of treatment including a single remind session 2 weeks 
after the first treatment block and display a short-time follow-up. 
The short-time treatment and follow-up of our protocol could 
obviously have impacted obtained results. The next research 
should take into account this point and should assess if a longer 
duration of our treatment model combining tDCS with MBCT 
might be even more efficient in order to reduce depression 
symptoms.
Second, about studying a sample of patients with resistant 
depression, some, such as Bennabi et al. (65), have suggested 
that tDCS efficacy diminishes in patients with high therapeutic 
resistance. Brunoni et al. (66) confirmed this observation in 
his study by showing that tDCS efficacy seems to be negatively 
correlated with the degree of treatment resistance. Not only could 
this observation have had an impact on our obtained results, but 
it would also be of major interest to explore the efficacy of our 
combined treatment model on a population of patients with a 
first depressive episode and non-drug-resistant depression.
Third, regarding an MBCT consideration, it is important 
to note that the MBCT program used in this study is normally 
delivered in eight weekly 2-h group training sessions. In 
our study, we have used a modified version of the classical 
program in order to directly combine the eight classical 
MBCT sessions with eight close tDCSs, that is, daily 2-h group 
training sessions. It might have affected the way patients have 
benefited of the MBCT tools, as the time accorded for their 
learning was shorter than initially defined. However, it has 
been proposed that most mindfulness-based interventions 
utilizing some forms of meditation practice result in objective 
cognitive and affective changes relative to the subtle and 
subjective shifts in awareness (67).
Also, the classical program proposed by Segal et al. (34) has 
initially been conceived as a program to prevent depressive 
relapses in stabilized patients, and not for acute depressed 
patients (34, 68), mostly because different cognitive, affective, 
and motivational characteristics of acute depression have been 
proposed to hinder the process of this specific 8-week therapy 
(68, 69). In our study, included patients presented a baseline score 
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of 23.13 (MBCT condition) and 24.75 (relaxation condition) at 
the MADRS. This observation may have impacted our results in 
the way the offered mindfulness program might not have been 
as effective as it should, considering the high depression scores 
of patients at baseline. However, other authors have showed that 
the MBCT program positively impacts depressive symptom 
severity (39).
Finally, the way we initially designed the protocol might 
have had an impact on obtained results. Indeed, the protocol 
design generates a lack of blinding of the investigator, who was 
the same person responsible of animating the two treatment 
groups. The way we combined tDCS and psychotherapeutic 
modalities might also have an impact. Indeed, our patients 
received their assigned psychotherapeutic modalities right 
after the tDCS. However, according to some authors, the time 
sequence between tDCS and psychotherapeutic practice could 
be a major issue, as synergic effects appear to be maximal when 
the active stimulation takes place during the psychotherapy 
rather than before it (70).
COnClUSiOn
The combined use of tDCS and mindfulness may be of 
interest in resistant depression patients: MBCT might provide 
a mechanism to keep the tDCS beneficial effects through time 
and even to improve them. Further research should definitely 
continue to investigate the adequate tDCS parameters and the 
efficacy of our combined treatment model in a population 
of patients with a first depressive episode and non-drug-
resistant depression and also in a greater sample size and 
should explore if a synergic effect could be enhanced when 
the active stimulation takes place during the psychotherapy 
rather than before it.
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